REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment#United_States#New_York#Wet_AMD#REGENXBIO#Surabgene_Lomparvovec
REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment
Mark your calendars! REGENXBIO will present key insights on surabgene lomparvovec during an investor event on October 20, 2026, shedding light on its pivotal trials.
third-news.com
October 12, 2026 at 11:08 AM
REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment#United_States#New_York#Wet_AMD#REGENXBIO#Surabgene_Lomparvovec
REGENXBIO Launches Revolutionary Phase IIb/III Trial for Diabetic Retinopathy Treatment#United_States#REGENXBIO#Diabetic_Retinopathy#Rockville,_MD#Surabgene_Lomparvovec
REGENXBIO Launches Revolutionary Phase IIb/III Trial for Diabetic Retinopathy Treatment
REGENXBIO has initiated a critical Phase IIb/III trial for its gene therapy in diabetic retinopathy, marking a significant milestone in vision care.
third-news.com
June 29, 2026 at 11:19 AM
REGENXBIO Launches Revolutionary Phase IIb/III Trial for Diabetic Retinopathy Treatment#United_States#REGENXBIO#Diabetic_Retinopathy#Rockville,_MD#Surabgene_Lomparvovec
REGENXBIO Launches Pivotal Phase IIb/III Trial for Diabetic Retinopathy Treatment#United_States#Rockville#REGENXBIO#Diabetic_Retinopathy#Surabgene_Lomparvovec
REGENXBIO Launches Pivotal Phase IIb/III Trial for Diabetic Retinopathy Treatment
REGENXBIO has announced the initiation of a crucial Phase IIb/III clinical trial for surabgene lomparvovec aimed at treating diabetic retinopathy.
third-news.com
August 7, 2025 at 11:05 AM
REGENXBIO Launches Pivotal Phase IIb/III Trial for Diabetic Retinopathy Treatment#United_States#Rockville#REGENXBIO#Diabetic_Retinopathy#Surabgene_Lomparvovec